botensilimab   Click here for help

GtoPdb Ligand ID: 14590

Synonyms: AGEN-1181 | AGEN1181
Immunopharmacology Ligand
Compound class: Antibody
Comment: Botensilimab (AGEN-11810) is a Fc-enhanced anti-CTLA-4 monoclonal antibody [5]. It is proposed as an immuno-oncology agent for the treatment of poorly immunogenic and treatment refractory cancers [4,8]. Heavy and light chain peptide sequences for botensilimab are claimed in patent US10912831B1 [9], nominally SEQ IDs 25 and 27 respectively, and these are the chains of clone AGEN1884.H3 therein.
References
1. Arce Vargas F, Furness AJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N, Roddie C et al.. (2018)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Cancer Cell, 33 (4): 649-663.e4. [PMID:29576375]
2. Bengala E, Santini D, Picone V. (2026)
Refractory microsatellite-stable metastatic colorectal cancer: a comparison between botensilimab + balstilimab and current standard of care.
Immunooncol Technol, 29: 101558. [PMID:41502912]
3. Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS et al.. (2024)
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.
Nat Med, 30 (9): 2558-2567. [PMID:38871975]
4. Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, Soh KT, Wu W, Wilkens MK, Udartseva O et al.. (2024)
Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.
Cancer Discov, 14 (12): 2407-2429. [PMID:39083809]
5. Delepine C, Levey D, Krishnan S, Kim KS, Sonabend A, Wilkens M, Tanne A, Garcia-Brocano P, Galand C, Han H et al.. (2022)
470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors.
J Immunother Cancer, 10: A490–A490. DOI: 10.1136/jitc-2022-SITC2022.0470
6. Kasi PM, Hidalgo M, Jafari MD, Yeo H, Lowenfeld L, Khan U, Nguyen ATH, Siolas D, Swed B, Hyun J et al.. (2023)
Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer.
Oncogene, 42 (44): 3252-3259. [PMID:37731056]
7. Porter R, Bockorny B, Corr BR, Mahadevan D, Wilky BA, El-Khoueiry AB, Bullock AJ, Hafez N, Moser J, Martynova A et al.. (2025)
Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.
J Immunother Cancer, 13 (12). [PMID:41436232]
8. Rudqvist NP, Avagyan M, Chand D. (2023)
Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy.
Oncoimmunology, 12 (1): 2275333. [PMID:37937212]
9. van Dijk M, Mundt CA, Ritter G, Schaer D, Wolchok JD, Merghoub T, Wilson NS, Savitsky DA, Finseis MA, Underwoo DJ et al.. (2021)
Anti-CTLA-4 antibodies and methods of use thereof.
Patent number: US10912831B1. Assignee: Ludwig Institute for Cancer Research Ltd Memorial Sloan Kettering Cancer Center, Agenus Inc. Priority date: 24/09/2020. Publication date: 09/02/2021.
10. Wilky BA, Schwartz GK, Gordon MS, El-Khoueiry AB, Bullock AJ, Henick B, Agulnik M, Singh A, Mahadevan D, Stebbing J et al.. (2025)
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.
J Clin Oncol, 43 (11): 1358-1368. [PMID:39869830]